Skip to main content

Table 1 Patient characteristics

From: Survival analysis of local excision vs total mesorectal excision for middle and low rectal cancer in pT1/pT2 stage and intermediate pathological risk

VariableTME (N = 134) number (%)LE (N = 39) number (%)P value
Age (y/o)63.0 ± 12.959.7 ± 13.90.178
BMI (kg/m2)24.3 ± 3.525.3 ± 4.40.226
Sex  1.000
 Male68 (50.7)20 (51.3) 
 Female66 (49.3)19 (48.7) 
Family cancer history43 (32.1)16 (41.0)0.339
CEA (ng/mL)2.88 ± 3.52.14 ± 1.10.757
Albumin < 3.5 (g/dL)8 (6.0)1 (2.9)0.688
Hemoglobin < 10 (g/dL)7 (5.2)1 (2.6)0.685
Ostomy  < 0.001
 No69 (51.5)36 (92.3) 
 Temporary50 (37.3)1 (2.6) 
 Permanent15 (11.2)2 (5.1) 
Adjuvant therapy21 (15.7)17 (43.6)< 0.001
 Chemotherapy*21 (15.7)**1 (2.6) 
 CCRT0 (0)**16 (41.0) 
Post-op morbidity38 (28.4)2 (5.1)0.002
 Early25 (18.7)2 (5.1)0.045
 Late22 (16.4)0 (0)0.005
  1. TME total mesorectal excision, LE local excision, BMI body mass index, CEA carcinoembryonic antigen, CCRT concurrent chemoradiation
  2. *Including tegafur and uracil in 17 patients, intravenous form 5-FU and leucovorin in 3 patients, and oxaliplatin plus intravenous 5-Fu/LV (FOLFOX) for 6 months in 1 patient
  3. **Including tegafur and uracil in 1 patient, tegafur, and uracil with long-course radiotherapy in 14 patients, and 5-FU/LV with long-course radiotherapy in 2 patients